Lipid metabolism in treated HIV infection

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 3, 2011, Pages 429-442

  Dubé, Michael P ^a   Cadden, Joseph J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cardiovascular risk; Human immunodeficiency virus; hypercholesterolemia; hypertriglyceridemia; lipid disorders; nucleoside reverse transcriptase inhibitors; protease inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FLUINDOSTATIN; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; INDINAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PITAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; RECOMMENDED DRUG DOSE;

EID: 79958291280     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2011.04.004     Document Type: Review

References (108)

1. M.P. Dubé, J.H. Stein, and J.A. Aberg Guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clinical Infectious Diseases 37 2003 613 627 (Pubitemid 37100800)
2. S.A. Riddler, X. Li, and H. Chu Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy HIV Medicine 8 5 2007 Jul 280 287 (Pubitemid 46901526)
3. S.A. Riddler, X. Li, and J. Otvos Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study Journal of Acquired Immune Deficiency Syndromes: JAIDS 48 3 2008 Jul 1 281 288
4. S. Grinspoon, and A. Carr Cardiovascular risk and body-fat abnormalities in HIV-infected adults New England Journal of Medicine 352 1 2005 Jan 6 48 62 (Pubitemid 40075680)
5. D. Wohl, R. Scherzer, and S. Heymsfield The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men Journal of Acquired Immune Deficiency Syndromes: JAIDS 48 1 2008 May 1 44 52 (Pubitemid 351600858)
6. J. Currier, R. Scherzer, and P. Bacchetti Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women Journal of Acquired Immune Deficiency Syndromes: JAIDS 48 1 2008 May 1 35 43 (Pubitemid 351600850)
7. J.H. Stein, L. Komarow, and B.A. Cotter Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s Journal of Clinical Lipidology 2 6 2008 464 471 (Pubitemid 352795714)
8. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2009 Department of Health and Human Services 1-161
9. D.A.D. Study Group, N. Friis-Moller, and P. Reiss Class of antiretroviral drugs and the risk of myocardial infarction New England Journal of Medicine 356 17 Apr 26 2007 1723 1735 (Pubitemid 46658704)
10. D.A.D. Study Group Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A:D study: a multi-cohort collaboration Lancet 371 2008 Apr 26 1417 1426
11. V.A. Triant, H. Lee, and C. Hadigan Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease Journal of Clinical Endocrinology & Metabolism 92 7 2007 Jul 2506 2512 (Pubitemid 47037350)
12. M.P. Dubé, S.E. Lipshultz, and C.J. Fichtenbaum Effects of HIV infection and antiretroviral therapy on the heart and vasculature Circulation 118 2 2008 Jul 8 e36 e40
13. S.K. Grinspoon, C. Grunfeld, and D.P. Kotler State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary Circulation 118 2 2008 Jul 8 198 210
14. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Journal of the American Medical Association (JAMA) 285 2001 2486 2497
15. S.M. Grundy, J.I. Cleeman, and C.N.B. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2 2004 Jul 13 227 239 (Pubitemid 38924592)
16. C. Grunfeld, D.P. Kotler, and J.K. Shigenaga Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome American Journal of Medicine 90 2 1991 154 162
17. C. Grunfeld, M. Pang, and W. Doerrler Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome Journal of Clinical Endocrinology and Metabolism 74 5 1992 1045 1052
18. D. Mildvan, S.G. Machado, and I. Wilets Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex Lancet 339 8791 1992 453 456
19. J. Baker, W. Ayenew, and H. Quick High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection Journal of Infectious Diseases 201 2 2010 Jan 15 285 292
20. M.P. Dubé, R.A. Parker, and P. Tebas Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides AIDS 19 2005 1807 1818 (Pubitemid 41546599)
21. F.J. Torriani, L. Komarow, and R.A. Parker Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s Journal of the American College of Cardiology 52 7 2008 Aug 12 569 576
22. J. Neuhaus, D.R. Jacobs Jr., and J.V. Baker Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection Journal of Infectious Diseases 201 12 2010 Jun 15 1788 1795
23. S.K. Gupta, R.M. Johnson, and K.J. Mather Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study AIDS 24 9 2010 Jun 1 1377 1380
24. S.K. Gupta, R.M. Johnson, and C. Saha Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study AIDS 22 5 2008 Mar 12 653 655 (Pubitemid 351640600)
25. J.M. Brenchley, D.A. Price, and T.W. Schacker Microbial translocation is a cause of systemic immune activation in chronic HIV infection Nature Medicine 12 12 2006 Dec 1365 1371 (Pubitemid 44924494)
26. L.L. Stoll, G.M. Denning, and N.L. Weintraub Potential role of endotoxin as a proinflammatory mediator of atherosclerosis Arteriosclerosis, Thrombosis & Vascular Biology 24 12 2004 Dec 2227 2236 (Pubitemid 39658022)
27. M. Troseid, P. Nowak, and J. Nystrom Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy AIDS 24 11 2010 Jul 17 1733 1737
28. M. Bukrinsky, and D. Sviridov Human immunodeficiency virus infection and macrophage cholesterol metabolism Journal of Leukocyte Biology 80 5 2006 Nov 1044 1051 (Pubitemid 44646310)
29. K. Wolf, D.A. Tsakiris, and R. Weber Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1 Journal of Infectious Diseases 185 4 2002 456 462 (Pubitemid 34142807)
30. L.H. Kuller, R. Tracy, and W. Belloso Inflammatory and coagulation biomarkers and mortality in patients with HIV infection PLoS Medicine/Public Library of Science 5 10 Oct 21 2008 e203
31. C. Hadigan, J.B. Meigs, and J. Rabe Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance Journal of Clinical Endocrinology & Metabolism 86 2 2001 939 943 (Pubitemid 32207521)
32. E.M. Young, R.V. Considine, and F.R. Sattler Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy Cardiovascular Toxicology 4 2 2004 179 268
33. P.E. Tarr, M. Rotger, and A. Telenti Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics Pharmacogenomics 11 4 2010 Apr 587 594
34. S.A. Bozzette, C.F. Ake, and H.K. Tam Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection New England Journal of Medicine 348 2003 702 710 (Pubitemid 36237039)
35. M. Mary-Krause, L. Cotte, and A. Simon Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men AIDS 17 17 2003 2479 2486 (Pubitemid 38393320)
36. J.H. Stein Dyslipidemia in the era of HIV protease inhibitors Progress in Cardiovascular Diseases 45 4 2003 293 304 (Pubitemid 36293025)
37. C.B. Hicks, P. Cahn, and D.A. Cooper Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials Lancet 368 9534 2006 Aug 5 466 475 (Pubitemid 44142769)
38. J. Eron Jr., P. Yeni, and J. Gathe Jr. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Lancet 368 9534 Aug 5 2006 476 482 [Erratum appears in Lancet. 2006 Oct 7;368(9543):1238] (Pubitemid 44160731)
39. A.M. Mills, M. Nelson, and D. Jayaweera Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS 23 13 Aug 24 2009 1679 1688
40. E. Fontas, F. van Leth, and C.A. Sabin Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Journal of Infectious Diseases 189 6 2004 Mar 15 1056 1074 (Pubitemid 38373099)
41. M. Kurowski, A.M. Hill, and C. Meocklinghoff Changes in lipid and laboratory parameters during treatment with saquinavir/ritonavir 1000/100 mg twice daily with no nucleoside reverse transcriptase inhibitors in healthy volunteers Antiviral Therapy 7 September 2002 22 25 L30
42. U.B. Dragsted, J. Gerstoft, and C. Pedersen Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial Journal of Infectious Diseases 188 5 Sep 1 2003 635 642 (Pubitemid 37115175)
43. R.L. Murphy, I. Sanne, and P. Cahn Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results AIDS 17 18 Dec 5 2003 2603 2614 (Pubitemid 38402338)
44. M.A. Noor, R.A. Parker, and E. O'Mara The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults AIDS 18 16 Nov 5 2004 2137 2144 (Pubitemid 39463678)
45. M.P. Dubé, C. Shen, and M. Greenwald No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial Clinical Infectious Diseases 47 4 Aug 15 2008 567 574
46. M. Kurowski, T. Sternfeld, and A. Sawyer Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers HIV Medicine 4 2 Apr 2003 94 100 (Pubitemid 36582291)
47. S.W. Worm, C. Sabin, and R. Weber Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D: A:D) study Journal of Infectious Diseases 201 3 Feb 1 2010 318 330
48. J.E. Gallant, S. Staszewski, and A.L. Pozniak Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial Journal of the American Medical Association (JAMA) 292 2 Jul 14 2004 191 201 (Pubitemid 38917996)
49. L. Calza, R. Manfredi, and V. Colangeli Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy AIDS Patient Care & Stds 23 2009 2043 2050
50. J.D. Kowalska, O. Kirk, and A. Mocroft Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir HIV Medicine 11 3 2010 Mar 200 208
51. C. Hadigan, J.B. Meigs, and C. Corcoran Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy Clinical Infectious Diseases 32 1 2001 130 139 (Pubitemid 32150958)
52. F. van Leth, P. Phanuphak, and K. Ruxrungtham Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2 NN Study Lancet 363 9417 Apr 17 2004 1253 1263 (Pubitemid 38496486)
53. F. Visnegarwala, M. Maldonado, and P. Sajja Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice Journal of Infection 49 4 Nov 2004 283 290 (Pubitemid 39341773)
54. M.J. Silverberg, W. Leyden, and L. Hurley Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection Annals of Internal Medicine 150 5 Mar 3 2009 301 313 [Summary for patients in Ann Intern Med. 2009 Mar 3;150(5):I38; PMID: 19258553]
55. F. Bonnet, E. Balestre, and R. Thiebaut Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001 HIV Medicine 5 3 May 2004 133 139 (Pubitemid 38765278)
56. C.A. Sabin, A. d'Arminio Monforte, and N. Friis-Moller Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction Clinical Infectious Diseases 46 7 Apr 1 2008 1101 1110 (Pubitemid 351589879)
57. Services UDoHaH Your Guide to Lowering Your Cholesterol with TLC 2005
58. L.J. Schwellenbach, K.L. Olson, and K.J. McConnell The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides Journal of the American College of Nutrition 25 6 Dec 2006 480 485 (Pubitemid 46175663)
59. R.M. Krauss, M. Winston, and R.N. Fletcher Obesity: impact of cardiovascular disease Circulation 98 14 Oct 6 1998 1472 1476
60. R. Elosua, L. Molina, and M. Fito Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women Atherosclerosis 167 2 Apr 2003 327 334 [Erratum appears in Atherosclerosis. 2008 Apr;197(2):967] (Pubitemid 36773532)
61. L. Brown, B. Rosner, and W.W. Willett Cholesterol-lowering effects of dietary fiber: a meta-analysis American Journal of Clinical Nutrition 69 1 Jan 1999 30 42 (Pubitemid 29031248)
62. B. Hansel, C. Nicolle, and F. Lalanne Effect of low-fat, fermented milk enriched with plant sterols on serum lipid profile and oxidative stress in moderate hypercholesterolemia American Journal of Clinical Nutrition 86 3 Sep 2007 790 796 (Pubitemid 47435849)
63. K. Henry, H. Melroe, and J. Huebesch Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities Lancet 352 9133 1998 1031 1032 (Pubitemid 28438577)
64. G.J. Moyle, M. Lloyd, and B. Reynolds Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy AIDS 15 2001 1503 1508 (Pubitemid 32744597)
65. E. Negredo, J. Ribalta, and R. Paredes Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine AIDS 16 2002 1383 1389 (Pubitemid 34722070)
66. N. Clumeck, F. Goebel, and W. Rozenbaum Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA AIDS 15 12 2001 1517 1526 (Pubitemid 32744599)
67. R. Murphy, A. Thiry, and M. Mancini Twelve weeks of atazanavir treatment reverses nelfinavir-associated hyperlipidaemia: results from BMS AI424-044 Antiviral Therapy 7 September 2002 22 25 L10
68. V. Soriano, P. Garcia-Gasco, and E. Vispo Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial Journal of Antimicrobial Chemotherapy 61 1 Jan 2008 200 205
69. J.J. Eron, B. Young, and D.A. Cooper Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials Lancet 375 9712 Jan 30 2010 396 407
70. M.J. Cupp, and T.S. Tracy Cytochrome P450: new nomenclature and clinical implications American Family Physician 57 1 Jan 1 1998 107 116 (Pubitemid 28063210)
71. C. Flexner HIV-protease inhibitors New England Journal of Medicine 338 18 Apr 30 1998 1281 1292 (Pubitemid 28216584)
72. D.M. Aboulafia, and R. Johnston Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease AIDS Patient Care & Stds 14 1 2000 13 18 (Pubitemid 30056634)
73. A. Hsu, G.R. Granneman, and R.J. Bertz Ritonavir Clinical pharmacokinetics and interactions with other anti-HIV agents Clinical Pharmacokinetics 35 4 Oct 1998 275 291 (Pubitemid 28491214)
74. J.R. King, and E.P. Acosta Tipranavir: a novel nonpeptidic protease inhibitor of HIV Clinical Pharmacokinetics 45 7 2006 665 682 (Pubitemid 43990569)
75. Prezista Prescribing Information 2010 Tibotec Therapeutics
76. D.A. Erickson, G. Mather, and W.F. Trager Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450 Drug Metabolism and Disposition 27 12 1999 1488 1495
77. L.L. von Moltke, D.J. Greenblatt, and B.W. Granda Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors Journal of Clinical Pharmacology 41 1 2001 85 91
78. M. Iwamoto, K. Kassahun, and M.D. Troyer Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation Journal of Clinical Pharmacology 48 2 Feb 2008 209 214
79. R. Hyland, M. Dickins, and C. Collins Maraviroc: in vitro assessment of drug-drug interaction potential British Journal of Clinical Pharmacology 66 4 Oct 2008 498 507
80. Canadian AIDS Treatment Information Exchange. Maraviroc-Absorption and Drug Interaction Issues S.R. Hosein Treatment Update 2007
81. G. Moyle Concurrent Use of Statins Does Not Influence Efficacy of Maraviroc in MOTIVATE Studies [abstract MOPEB039]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 2009 2009 Cape Town, South Africa; 2009
82. Isentress (raltegravir) Prescribing Information June 2010 Merck & Co. Inc USA
83. C.J. Fichtenbaum, and J.G. Gerber Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection Clinical Pharmacokinetics 41 14 2002 1195 1211 (Pubitemid 35398692)
84. C.J. Fichtenbaum, J.G. Gerber, and S.L. Rosenkranz Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 AIDS 16 4 2002 569 577 (Pubitemid 34218852)
85. P.H. Hsyu, M.D. Schultz-Smith, and J.H. Lillibridge Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin Antimicrobial Agents & Chemotherapy 45 12 2001 3445 3450 (Pubitemid 33107860)
86. J.G. Dain, E. Fu, and J. Gorski Biotransformation of fluvastatin sodium in humans Drug Metabolism & Disposition 21 4 Jul-Aug 1993 567 572
87. G.M. Ray Antiretroviral and statin drug-drug interactions Cardiology in Review 17 1 Jan-Feb 2009 44 47
88. N. Doser, S. Kübli, and A. Telentic Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients AIDS 16 2002 1982 1983
89. K.T. Kivisto, T. Kantola, and P.J. Neuvonen Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin British Journal of Clinical Pharmacology 46 1 1998 49 53 (Pubitemid 28308424)
90. L. Calza, V. Colangeli, and R. Manfredi Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study AIDS 19 10 Jul 1 2005 1103 1105 (Pubitemid 40961152)
91. J.W.M. Cheng Rosuvastatin in the management of hyperlipidemia Clinical Therapeutics 26 9 Sep 2004 1368 1387 (Pubitemid 39572152)
92. K.J. Cooper, P.D. Martin, and A.L. Dane Effect of itraconazole on the pharmacokinetics of rosuvastatin Clinical Pharmacology & Therapeutics 73 4 Apr 2003 322 329 (Pubitemid 36403592)
93. J.J. Kiser, J.G. Gerber, and J.A. Predhomme Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers Journal of Acquired Immune Deficiency Syndromes: JAIDS 47 5 Apr 15 2008 570 578 (Pubitemid 351442013)
94. R.Y.A. Mukhtar, J. Reid, and J.P.D. Reckless Pitavastatin International Journal of Clinical Practice 59 2 Feb 2005 239 252 (Pubitemid 40331227)
95. Livalo (pitavastatin) Package Insert 2010 Kowa Pharmaceuticals USA
96. B. Coll, G. Aragones, and S. Parra Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients AIDS 20 12 Aug 2006 1 1675 1677 (Pubitemid 44162414)
97. E. Negredo, J. Molto, and J. Puig Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins AIDS 20 17 Nov 14 2006 2159 2164 (Pubitemid 44684706)
98. J. Miller, D. Brown, and J. Amin A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia AIDS 16 16 2002 2195 2200 (Pubitemid 35387274)
99. J.A. Aberg, R.A. Zackin, and S.W. Brobst A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087 AIDS Research & Human Retroviruses 21 9 Sep 2005 757 767 (Pubitemid 41434180)
100. J.G. Gerber, D.W. Kitch, and C.J. Fichtenbaum Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 Journal of Acquired Immune Deficiency Syndromes: JAIDS 47 4 Apr 1 2008 459 466 (Pubitemid 351366958)
101. L. Calza, R. Manfredi, and F. Chiodo Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART Infection 30 1 2002 26 31 (Pubitemid 34146409)
102. P.H. Jones, and M.H. Davidson Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin American Journal of Cardiology 95 1 Jan 1 2005 120 122 (Pubitemid 40051126)
103. Welchol Prescribing Information 2010 Daiichi Sankyo Inc
104. M.P. Dubé, J.W. Wu, and J.A. Aberg Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148 Antiviral Therapy 11 8 2006 1081 1089 (Pubitemid 44955184)
105. W.J. Fessel, S.E. Follansbee, and J. Rego High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution AIDS 16 13 2002 1785 1789
106. M.T. Gerber, K.E. Mondy, and K.E. Yarasheski Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy Clinical Infectious Diseases 39 3 Aug 1 2004 419 425 (Pubitemid 39050492)
107. J.J.P. Kastelein, F. Akdim, and E.S.G. Stroes Simvastatin with or without ezetimibe in familial hypercholesterolemia New England Journal of Medicine 358 14 Apr 3 2008 1431 1443 (Pubitemid 351482735)
108. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness New England Journal of Medicine Nov 15 2009